Zavegepant
Zavegepant is an intranasal calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) that blocks CGRP-mediated vasodilation and neurogenic inflammation in trigeminovascular pathways implicated in migraine pathophysiology. It is approved for acute treatment of migraine in adults as an intranasal spray, providing an alternative to oral gepants for patients who prefer non-oral administration or experience nausea. Its intranasal route offers rapid absorption across the nasal mucosa for faster onset.
분자량
638.8000 g/mol
LogP
3.10
TPSA
117.00 Ų
리핀스키 5의 법칙
통과
치료 영역
작용 기전
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
2D 구조
Cite this structure
Embed this structure
SMILES
Cc1cc(C[C@@H](NC(=O)N2CCC(c3cc4ccccc4[nH]c3=O)CC2)C(=O)N2CCN(C3CCN(C)CC3)CC2)cc2cn[nH]c12
InChI
InChI=1S/C36H46N8O3/c1-24-19-25(20-28-23-37-40-33(24)28)21-32(35(46)43-17-15-42(16-18-43)29-9-11-41(2)12-10-29)39-36(47)44-13-7-26(8-14-44)30-22-27-5-3-4-6-31(27)38-34(30)45/h3-6,19-20,22-23,26,29,32H,7-18,21H2,1-2H3,(H,37,40)(H,38,45)(H,39,47)/t32-/m1/s1
Molecular Formula
C36H46N8O3
HBD / HBA
3 / 6
회전 가능 결합
6
무거운 원자
47
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
자주 묻는 질문
Zavegepant is an intranasal calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) that blocks CGRP-mediated vasodilation and neurogenic inflammation in trigeminovascular pathways implicated in migraine pathophysiology. It is approved for acute treatment of migraine in adults as an intranasal spray, providing an alternative to oral gepants for patients who prefer non-oral administration or experience nausea. Its intranasal route offers rapid absorption across the nasal mucosa for faster onset.
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Yes, Zavegepant is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2397415. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 53472683. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="zavegepant"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/zavegepant/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/zavegepant/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/zavegepant/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="zavegepant"></drugfyi-drug>